This article presents the stock performance of each of the 12 largest American cannabis multi-state operators (MSOs) in the munKNEE American Cannabis MSOs Index this week and in the last 6 weeks in descending order, as follows:

1. TerrAscend (TRSSF): 
   • DOWN 6.6% this week and
   • UP 24.0% since the end of January (6 weeks)
     • Has a 64% Chance of Financial Distress within 2 years;
   • Average price target is $2.05, a 32.3% increase from the March 10th price of $1.55
     • The highest analyst price target is $2.20, the lowest forecast is $1.75
     • Consensus rating of Moderate Buy is based on 2 buy ratings, 1 hold rating and 0 sell ratings of 3 Wall Street analyst offering 12 month price targets for TerrAscend in the last 3 months Source
   • Read:
     • TerrAscend Q3 Financial Report Reveals Major Declines In Income And EBITDA
     • TerrAscend Hopes The USA Can Provide A Future It Controls
2. Verano (VRNOF): 
   • UP 4.3% this week and
   • UP 10.9% since the end of January (6 weeks)
     • Has a 64% Chance of Financial Distress within 2 years;
   • Average analyst price target is $9.83, a 212.7% increase from the March 10th price of $3.16
     • The highest analyst price target is $16.17, the lowest forecast is $3.31
     • Consensus rating of Strong Hold is based on 3 buy ratings, 1 hold rating and 0 sell ratings of 4 Wall Street analyst offering 12 month price targets for Verano in the last 3 months. Source
   • Read:
     • Verano Q3 Financial Report Reveals Major Increase In Net Loss
     • Verano: A Top Cannabis Pick For 2023
3. Green Thumb (GTBIF): 
   • DOWN 4.1% this week and
   • UP 8.0% since the end of January (6 weeks)
     • Is the only MSO with a  Positive Net Operating Cash Flow
     • Has a 10% Chance of Financial Distress within 2 years;
   • Average analyst price target is $15.29, a 88.8% increase from the March 10th price of $8.10
     • The highest analyst price target is $23.52, the lowest forecast is $10.00
     • Consensus rating of Strong Buy is based on 6 buy ratings, 1 hold ratings and 0 sell ratings of 7 Wall Street analysts offering 12 month price targets for Green Thumb in the last 3 months Source
   • Read:
     • Green Thumb Reports Record Revenue And Adjusted Operating EBITDA
     • Green Thumb Industries: Best Of Breed In U.S. Cannabis
4.  Cresco Labs (CRLBF): 
   • UP 0.6% this week and
   • UP 2.2% since the end of January (6 weeks)
     • Has a 76% Chance of Financial Distress within 2 years;
   • Average analyst price target is $5.19, a +185.2% increase from the March 10th price of $1.82
     • The highest analyst price target is $4.00, the lowest forecast is $1.75
     • Consensus rating of Moderate Buy is based on 1 buy rating, 1 hold rating and 0 sell ratings of 2 Wall Street analyst offering 12 month price targets for Cresco Labs in the last 3 months Source
   • Read:
     • Cresco Labs Q3 Financials Show No Improvement Over Q2 Results
     • Cresco Labs: An Unloved U.S. Cannabis Multi-State Operator
5. Curaleaf (CURLF): 
   • DOWN 3.9% this week and
   • DOWN 1.6% since the end of January (6 weeks)
     • Has a 39% Chance of Financial Distress within 2 years;
   • Average analyst price target is $7.42, a 100.5% increase from the March 10th price of $3.70
     • The highest analyst price target is $12.00, the lowest forecast is $5.00
     • Consensus rating of Strong Buy is based on 4 buy ratings, 0 hold ratings and 0 sell ratings of 4 Wall Street analysts offering 12 month price targets for Curaleaf in the last 3 months Source
   • Read:
     • Curaleaf Q3 Report Reveals 80% Decrease In Net Profit
     • Curaleaf: Former Leader In U.S. Cannabis Remains Buyable
6. Planet 13 (PLNHF): 
   • No Change this week and
   • DOWN 4.4% since the end of January (6 weeks)
     • Has a 46% Chance of Financial Distress within 2 years;
   • Average analyst price target is $0.95, a 10.5% increase from the March 10th price of $3.85
     • The highest analyst price target is $0.95, the lowest forecast is $0.95
     • Consensus rating of Hold is based on 0 buy ratings, 1 hold rating and 0 sell ratings of 1 Wall Street analyst offering 12 month price targets for Planet 13 in the last 3 months Source
   • Read:
     • Planet 13 Financial Metrics In Q3 All Declined
     • Planet 13 Is Down But Not Out In The Cannabis Industry
7. Jushi (JUSHF):
   • DOWN 4.7% this week and
   • DOWN 6.2% since the end of January (6 weeks)
     • Has a 71% Chance of Financial Distress within 2 years;
   • Analyst forecasts not available
   • Read:
     • Jushi Holdings Releases Mixed Preliminary Q3 Financials
     • Jushi Holdings: Still Trading At A Distressed Valuation
8. Trulieve (TCNNF): 
   • DOWN 4.0% this week and
   • DOWN 6.9% since the end of January (6 weeks)
     • Has a 69% Chance of Financial Distress within 2 years;
   • Average analyst price target is $14.25, a 136.3% increase from the March 10th price of $6.03
     • The highest analyst price target is $14.25, the lowest forecast is $14.25
     • Consensus rating of Moderate Buy is based on 1 buy rating, 0 hold ratings and 0 sell ratings of 1 Wall Street analyst offering 12 month price targets for Trulieve in the last 3 months Source
   • Read:

     •  Trulieve Q4 Financials: Revenue Static; Net Loss Reduced By 33%

9. Ascend (AAWH): 

   • DOWN 6.2% this week and
   • DOWN 7.7% since the end of January (6 weeks)
     • Has a 74% Chance of Financial Distress within 2 years;
   • Average analyst price target is $2.88, a +140.0% increase from the March 10th price of $1.20
     • • The highest analyst price target is $4.00, the lowest forecast is $1.75
       • Consensus rating of Moderate Buy is based on 1 buy rating, 1 hold rating and 0 sell ratings of 2 Wall Street analyst offering 12 month price targets for Ascend in the last 3 months Source
   • Read:
     • Ascend Wellness Q3 Report: Record Revenue, Adjusted Gross Profit, And EBITDA Margin
     • Ascend Wellness: Thriving Without New York
10. Columbia Care (CCHWF): 
    • DOWN 1.6% this week and
    • DOWN 17.8% since the end of January (6 weeks)
      • Has a 72% Chance of Financial Distress within 2 years;
    • Average analyst price target is $1.15, a 91.7% increase from the March 10th price of $0.60
      • The highest analyst price target is $1.15, the lowest forecast is $1.15
      • Consensus rating of Hold is based on 0 buy ratings, 2 hold ratings and 0 sell ratings of 2 Wall Street analyst offering 12 month price targets for Columbia Care in the last 3 months Source​​​​​​​
    • Read:
      • Columbia Care Reports Third Quarter 2022 Results
      • ​​​​​​​Cannabis Company Columbia Care Is A Bargain
11. Acreage Holdings (ACRDF/ACRHF):
    • DOWN 11% this week and
    • DOWN 23.7% since the end of January (6 weeks)
      • Has a 80% Chance of Financial Distress within 2 years;
    • Analyst forecasts not available
    • Read:
      • Acreage Reports Third Quarter 2022 Financial Results
      • Cresco Labs, Columbia Care M&A deal closure extended to June
12. Ayr (AYRWF):
    • DOWN 31.5% this week and
    • DOWN 42.6% since the end of January (6 weeks)
      • Chance of Financial Distress within 2 years: N/A;
    • Average analyst price target is $3.07, a 314.9% increase from the March 10th price of $0.74
      • The highest analyst price target is $4.75, the lowest forecast is $1.38
      • Consensus rating of Moderate Buy is based on 1 buy rating, 1 hold rating and 0 sell ratings of 2 Wall Street analyst offering 12 month price targets for Columbia Care in the last 3 months Source
    • Read:

      •  Ayr Wellness Q4 Financials: Operating Loss Increases; EBITDA Improves

More By This Author:

5 Largest Canadian Cannabis LPs - 13% This Week; -26% In Last 6 Weeks
Ayr Wellness Q4 Financials: Operating Loss Increases; EBITDA Improves
MindMed: Researching LSD And MNMA To Treat Neurological Diseases